Related Experiment Video
Updated: Jun 9, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Cystic Fibrosis-Asthma Overlap Syndrome: Current Understanding and Future Directions.
Irina Miralda1, Daniel S Aridgides2, Hazel Ozuna1
1Department of Pediatrics, Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio, USA.
Cystic fibrosis-asthma overlap syndrome (CFAOS) is poorly defined, but type 2 inflammation may identify patients who benefit from targeted therapies. Further research is needed for better diagnosis and treatment.
Area of Science:
- Pulmonology
- Immunology
- Genetics
Background:
- Cystic fibrosis-asthma overlap syndrome (CFAOS) affects many people with CF (pwCF) but lacks clear diagnostic and treatment guidelines.
- Asthmatic type 2 (T2) inflammation is linked to worse outcomes in pwCF, yet standard asthma diagnostics are insufficient due to overlapping CF lung disease phenotypes.
- Current treatments for CFAOS are used inconsistently, leading to varied patient benefits.
Purpose of the Study:
- To review current diagnostic and therapeutic strategies for CFAOS.
- To examine the role of T2 inflammation in the pathophysiology of CF.
- To identify research priorities for classifying CF subgroups and improving treatment.
Main Methods:
- A comprehensive literature search was performed using the PubMed database.
- Searched terms included asthma diagnosis and treatment, T2 inflammation markers in pwCF, and CFAOS.
- The review focused on peer-reviewed publications.
Main Results:
- CFTR deficiency in immune cells may increase T2 stimuli response, contributing to higher asthma incidence in pwCF.
- Genetic and environmental factors also influence T2 inflammation in pwCF.
- Biomarkers are crucial for identifying pwCF who will respond to targeted asthma biologic therapies.
Conclusions:
- There is a significant need for improved methods to diagnose asthma in pwCF.
- Utilizing biomarkers can help personalize asthma treatment strategies for pwCF.
- Further research is essential to define clinically relevant subgroups within CFAOS.
More Related Videos
06:57The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
Published on: May 8, 2017
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma I: Introduction
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: